Recombinant adeno-associated virus acid alpha-glucosidase (University of Florida)

N/A

Report date: 2023/10/26 16:14:40

Base Information

Drug NameRecombinant adeno-associated virus acid alpha-glucosidase (University of Florida)
Drug Alias NamePompe disease adeno-associated virus gene therapyrAAV1-CMV-GAAAAV9-GAA IMrAAV9-DES-hGAA
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionAcidic alpha-glucosidase modulators
TargetsAcidic alpha-glucosidase
Therapy Area/IndicationsGlycogen Storage Disease Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Florida
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Florida
Active IndicationsN/A
Inactive IndicationsGlycogen Storage Disease Type II

Other Information

ATC CodeN/A
Related LinksN/A